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Pre-clinical and clinical evidence suggest that bisphosphonates inhibit both bone resorption and cancer progression. New and updated
analyses from several large, controlled studies in pre- and post-menopausal women with early stage breast cancer (BC) suggest that
addition of bisphosphonates improves cancer-related outcomes, particularly in patients with a ‘low-estrogen environment’. Further, preliminary clinical data suggest that bisphosphonate therapy may reduce circulating tumour cell numbers (a negative prognostic indicator
of disease-free and overall survival) in patients with advanced/metastatic disease. These new findings warrant reconsideration of the
therapeutic role of bisphosphonates in BC.
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Introduction
Bisphosphonates are the most common pharmaceutical intervention for prevention of skeletal-related events (SREs) in patients with
malignant skeletal involvement. Data from several studies suggest that in addition to inhibiting bone resorption, bisphosphonates may limit
cancer progression through their effects within the bone (e.g. cancer cell–bone interactions) or their effects on extraskeletal processes such
as host antitumour immunity, angiogenesis, and circulating tumour cells (CTCs). The potential of simultaneously limiting bone resorption
and tumourigenesis by bisphosphonates is therapeutically relevant, and accordingly, several large, clinical programs have evaluated the
anticancer benefits of adding bisphosphonates to standard-of-care in the adjuvant setting in earlier stage breast cancer (BC) and in patients
with advanced/metastatic BC. These studies shed light on the anticancer benefits of bisphosphonate therapy and the subsets of patients
who may benefit from such therapy. Recently, several large, controlled studies in patients with earlier stage disease reported data suggestive
of potential anticancer benefit of zoledronic acid (ZOL) in particular patient subsets. In addition, smaller studies suggest that ZOL may have
similar anticancer benefits in patients with advanced/metastatic disease. These data warrant reconsideration of clinical practice in early BC
and further clinical exploration of the therapeutic role of bisphosphonates in advanced BC.

Several trials have demonstrated the anticancer benefit of adding bisphosphonates to standard adjuvant treatment in patients with early
stage disease (Table 1) [1–5]. For example, in the ABCSG-12 study in pre-menopausal patients with early BC undergoing complete
estrogen blockade (a patient population highly susceptible to bone loss), 3 years’ ZOL treatment (4 mg every 6 months) significantly
improved disease-free survival (DFS) at the 48-month follow-up (hazard ratio [HR] = 0.74; log-rank P = 0.01); moreover, these benefits
were maintained at 62 (HR = 0.68; log-rank P = 0.008), 76 (HR = 0.73; log-rank P = 0.02), and 84 months (HR = 0.71; log-rank P = 0.011),
demonstrating potential carryover anticancer benefit persisting for 4–5 years after treatment cessation [2]. Moreover, at the 84-month
follow-up, analysis of overall survival (OS) showed that ZOL decreased risk of death versus placebo (HR = 0.61; P = 0.033) and that this
benefit appeared to be driven by the subset of patients >40 years of age (HR = 0.57; P = 0.042).
In the NSABP-B34 study evaluating the benefit of adding clodronate to adjuvant therapy in patients with earlier stage BC, clodronate
treatment was associated with significant improvement in non-bone metastasis-free survival (HR = 0.743; P = 0.046), although there was
no observable difference between treatment arms in the DFS primary endpoint (HR = 0.91; P = 0.27) [3]. More importantly, however,
anticancer benefits were more marked in the subset of patients >50 years of age (recurrence-free interval: HR = 0.76, P = 0.05; bone
metastases-free interval [BMFI]: HR = 0.61, P = 0.024; non-BMFI: HR = 0.63, P = 0.015; OS: HR = 0.80, P = 0.1) [3].
Consistent with these data, Coleman et al reported that although adjuvant ZOL had no effect on survival in the overall study population
of BC patients in the AZURE trial, ZOL was associated with survival benefit in the subset of patients with a low-estrogen environment
(>5 years post-menopause at study entry) [6]. Similarly, in an exploratory analysis of data from the ZO-FAST study, initiation of ZOL
concurrent with standard adjuvant therapy significantly improved survival (HR = 0.50, P = 0.0224) in early stage BC patients who
were >5 years post-menopause or >60 years of age [7]. In the GAIN study, a similar trend toward improved survival was noted in
ibandronate-treated patients ≥60 years of age (HR = 0.746, P = 0.172) [4].
More recently, the novel receptor activator of nuclear factor kappaB ligand (RANKL)-directed antibody denosumab was shown to
significantly increase bone mineral density (BMD) over 24 months at trabecular and cortical bone in women with non-metastatic BC and
low-bone mass receiving adjuvant aromatase inhibitor therapy [8]. However, it should be noted that the effects of denosumab on BMD
are relatively transient, as was observed in a study that evaluated the effects of discontinuing and restarting denosumab treatment in
post-menopausal women with low-bone mass [9]. In this study, discontinuation of denosumab was associated with a BMD decrease of
6.6% at the lumbar spine and 5.3% at the total hip within the first 12 months after stopping treatment. This was paralleled by an increase
in bone turnover marker levels as early as six months after discontinuation of denosumab treatment at dose levels comparable with those
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used in the early BC setting. These rates of bone loss were higher than those observed in placebo-treated patients at any point during the
study. Although BMD benefits were restored by re-treatment, this rebound effect needs further consideration as this may be reflective of a
bone microenvironment more conducive to tumour recurrence.
Thus, several large studies independently corroborate the benefit of bisphosphonates in the early BC setting in older or post-menopausal
patients (low-estrogen environment) and support inclusion of ZOL as standard treatment for these patients. Further, these studies show
that treatment with adjuvant bisphosphonates is safe and may provide sustained anticancer benefit—desirable treatment characteristics
for this patient population with good prognosis and prone to recurrent disease.
Table 1: Controlled studies of antiresorptive agents in breast cancer.
Study

Study description

Key results

Coleman et al
(AZURE) [1]

Placebo-controlled phase III study evaluating the
benefit of ZOL in patients with early stage BC

No OS differences in overall population; however, subset
analysis in patients showed that:
• Among post-menopausal patients, the 5-year rate of
invasive DFS was 78.2% in the ZOL group and 71.0%
in the control group (HR = 0.75; P = 0.02)
• Among patients who had undergone menopause >5 years
before study entry, the 5-year OS rate was 84.6% in the
ZOL group versus 78.7% in the control group (HR = 0.74;
P = 0.04)

Gnant et al
(ABCSG-12) [2]

Placebo-controlled phase III study evaluating the
benefit of ZOL in pre-menopausal patients with early
stage BC

DFS benefits observed at 48-month follow-up
(HR = 0.74; log-rank P = 0.01) were maintained at
84 months (HR = 0.71; log-rank P = 0.011). Subset
analyses at the 84-month follow-up show that DFS
benefits appear to be driven by patients >40 years of age

Paterson et al
(NSABP–B34) [3]

Placebo-controlled phase III study evaluating
the benefit of oral clodronate in pre- and postmenopausal patients with non-metastatic BC
stratified by HR and nodal status, and by age <50
or ≥50 years

In patients ≥50 years of age, clodronate improved:
• RFI: HR = 0.76; P = 0.05
• BMFI: HR = 0.61; P = 0.024
• nBMFI: HR = 0.63; P = 0.015
• OS: HR = 0.80; P = 0.1

Mobus et al
(GAIN) [4]

Randomized controlled, 2 × 2, factorial design trial
of epirubicin, paclitaxel, and cyclophosphamide
versus epirubicin, cyclophosphamide, paclitaxel,
and capecitabine, each followed by either daily
ibandronate or observation in patients with newly
diagnosed, node-positive BC

No difference in the 3-year DFS (HR = 0.945; P = 0.59) or
the 3-year OS (HR = 1.04; P = 0.80) between ibandronate
versus observation in the ITT population

Randomized phase III study comparing denosumab
versus ZOL in patients with bone mets from
advanced BC

Denosumab was superior to ZOL in delaying time to first
on-study SRE (HR = 0.82; P = 0.01 superiority) and time
to first and subsequent on-study SREs (rate ratio = 0.77;
P = 0.001). No difference in survival or disease progression
was noted

Advanced disease
Stopeck et al
(Amgen 136) [5]

BMFI bone metastasis-free interval, DFS disease-free survival, HR hazard ratio, ITT intent to treat, nBMFI non-bone metastasis-free
interval, OS overall survival, RFI recurrence-free interval, SRE skeletal-related event, ZOL zoledronic acid
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Advanced disease

The effect of antiresorptives on cancer-related outcome may be influenced by both drug- and disease-related factors. First, nitrogen-containing
bisphosphonates target a broad range of intracellular signal transduction intermediates, whereas denosumab acts exclusively by binding
RANKL. Second, bisphosphonates have little or no systemic availability, unlike denosumab, so their effects are largely confined to bone.
Conceivably, cancer-related outcomes may be influenced by effects on bone resorption alone, effects on tumour cells, or both. In addition,
tumour type and disease burden may both be important determinants of treatment outcome. For example, in patients with multiple myeloma,
wherein the majority of the cancer resides within the bone marrow, post-hoc analyses of phase III trial data in patients with malignant bone
disease showed that, although patients with solid tumours had similar cancer-related outcomes, denosumab was associated with an increased
risk of death versus ZOL in this subset of patients (HR = 2.26; 95% CI = 1.13–4.50; n = 180) [10, 11]. It is not currently known whether
there may be a difference in treatment response based on number or size of bone lesions at baseline. However, exploratory analyses
suggest that patients with bone metastases and elevated levels of osteolysis at baseline have improved survival with ZOL versus placebo
[12, 13]. Moreover, control of skeletal disease may improve cancer-related outcomes, as suggested by a retrospective analysis showing that
ZOL-mediated normalization of bone-turnover markers in patients with bone metastases from BC (N = 548) and elevated baseline osteolysis
levels was associated with improved survival versus patients whose bone marker levels remained elevated (relative risk = 0.52; 95% CI =
0.34–0.78; P = 0.0017) [14].
The minimal inference from these data is that a reduction in bone turnover markers in patients with skeletal involvement is associated with
improved outcomes, and that with the availability of new agents, clinicians may now consider sequencing of bone-conserving therapies.
Recently, it was shown that denosumab may lower bone turnover markers in patients with elevated levels after previous bisphosphonate
treatment [15]. However, it is unclear whether this denosumab-mediated normalization of bone markers correlates with improvements
in disease outcomes. The role of markers in comparing treatment options therefore requires further study. Further trials are also needed
to optimize sequencing strategies and dosing regimens as well as to identify baseline prognostic factors that may inform treatment
decisions.
In addition to the effects in bone, ZOL may improve cancer-related outcome through extraskeletal effects. For example, recent exploratory
data from the Z-ACT1 study show that ZOL induced rapid and sustained decrease in the proportion of metastatic BC patients (N = 29) with
CTCs ≥5 (55% at baseline to 25% and 15% at study months 1 and 4, respectively) and, moreover, that patients with CTCs <5 had longer
progression-free survival versus patients with CTCs ≥5 (296 versus 106 days; CTCs assessed at weeks 3–5) [16]. It should be noted that
patient numbers from this study are small, and the effects of ZOL on cancer-related outcomes need to be confirmed in larger, prospective
trials. However, these data are consistent with known prognostic significance of CTC level in metastatic BC [17, 18], and emerging evidence
showing that ZOL decreases median CTC basal value from 20 (range, 0–981) to 10 cells (range, 0–362; P = 0.009) in BC patients with
bone metastases [19]. These effects on CTCs are analogous to previously documented suppressive effects of ZOL on disseminated
tumour cells [20]. These data warrant further prospective study of the anticancer benefit of bisphosphonates in metastatic BC patients
prospectively stratified by baseline CTC status.
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The results of a randomized, controlled phase III trial comparing denosumab with ZOL in patients with advanced BC and at least one
bone lesion demonstrated that denosumab significantly delayed the time to first on-study SRE (non-inferiority P < 0.001), the primary
non-inferiority and secondary superiority endpoint of the study [5]. In addition, denosumab prolonged time to first and subsequent on-study
SREs (P = 0.001). There were no differences in time to disease recurrence or overall survival. The data imply that the effects of either
antiresorptive on the natural progression of malignancy are similar. However, survival differences may yet emerge with longer follow-up.
Moreover, patients who went off study would likely have received bisphosphonates, a standard of care in this setting, and the effects of
those and other off-study treatments on survival in this trial are unknown.
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Conclusions
With the availability of several antiresorptive agents, it is conceivable that skeletal- and cancer-related benefits may be considered
collectively during treatment decisions throughout the disease continuum. Furthermore, the overall benefit may be optimized using patientselection strategies based on menopausal status, age, CTCs, and/or bone metabolism markers. In addition to long-term risk–benefit
considerations relating to bone health, the potential of antiresorptives to affect cancer-related outcomes may become an important
consideration for treatment choice. Recent clinical evidence showing the potential anticancer activity of bisphosphonates, especially ZOL,
suggests that re-evaluation of the benefits and roles of antiresorptive therapies is warranted.
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